GET DAILY SIGNALSDexCom (DXCM): Leading the Way in Continuous Glucose Monitoring
Key Takeaways
- DexCom, Inc. (DXCM) is a medical device company that designs and sells continuous glucose monitoring (CGM) systems for people with diabetes.
- The company was founded in 1999 and is headquartered in San Diego, California, trading on the Nasdaq since 2005.
- Its flagship products include the Dexcom G7 sensor and Stelo, an over-the-counter (OTC) glucose biosensor, generating recurring revenue from disposable sensors.
- DexCom operates in a largely two-player CGM market, competing primarily against Abbott and, to a lesser extent, Medtronic and Senseonics.
- The business is driven by an expanding installed base of users, broad reimbursement coverage, and integration with automated insulin delivery systems.
An Overview of DexCom's Focus
DexCom, Inc. is a medical device company focused on continuous glucose monitoring (CGM) technology for diabetes management. A CGM is a small wearable sensor placed under the skin that measures glucose levels in real time and sends readings to a smartphone or receiver, reducing or eliminating the need for routine fingerstick blood tests. Investors follow DXCM because the company is a leader in a fast-growing market driven by rising diabetes prevalence, expanding insurance coverage, and a shift toward sensor-based diabetes care. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
DexCom's Journey and Background
DexCom was founded in 1999 in San Diego, California, and is headquartered there today. The company completed its initial public offering (IPO) in 2005 and is listed on the Nasdaq under the ticker DXCM. DexCom launched its first sensor in 2004 and has since introduced a series of increasingly advanced CGM systems. Notable milestones include the FDA approval of the seven-day Dexcom SEVEN system in 2007, the G6 system in 2018, which required no fingersticks, and the G7 platform, the company's current-generation flagship.
How DexCom Generates Revenue Through Its Products
DexCom's product portfolio centers on a "razor-and-blade" business model: customers receive a reusable transmitter and a compatible smart device or receiver, while the company earns the bulk of its revenue from recurring sales of disposable sensors that users replace on a regular schedule. Key products include:
- Dexcom G7 — the current-generation CGM sensor, smaller and simpler to apply than prior versions, and central to the company's growth strategy.
- Dexcom G6 — the prior flagship platform, which retained a large installed base during the transition to G7.
- Dexcom ONE/ONE+ — simplified offerings sold in certain international markets to broaden access.
- Stelo — an OTC glucose biosensor cleared by the U.S. FDA in 2024, designed for adults with prediabetes and Type 2 diabetes who do not use insulin. Stelo represents DexCom's expansion beyond the prescription market into direct-to-consumer sales.
- Software and data tools — apps and platforms such as Dexcom Clarity and Dexcom Follow that support data sharing, remote monitoring, and clinical reporting.
DexCom's revenue is generated primarily through disposable sensor sales, which have historically represented the large majority of total revenue. The company sells through pharmacies, durable medical equipment distributors, and, increasingly, direct consumer channels. Its products also integrate with insulin pumps from partners such as Insulet and Tandem Diabetes Care to enable automated insulin delivery, strengthening the company's ecosystem and customer retention.
DexCom's Place in the Competitive Landscape
DexCom is one of the two dominant players in the global CGM market, competing most directly with Abbott and its FreeStyle Libre line of sensors. Other competitors include Medtronic, which offers CGM systems tied to its insulin pumps, and smaller players such as Senseonics. DexCom's competitive position rests on the accuracy and reliability of its sensors, its large installed base of users, strong relationships with clinicians and payers, and integration with leading insulin delivery systems. From what I see, this dual-player dynamic keeps the focus on innovation and reliability.
Reasons Investors Track DXCM
Investors pay close attention to DXCM for several long-term reasons. First, the addressable market is large and expanding: diabetes affects hundreds of millions of people worldwide, and CGM penetration remains relatively low, especially among people with Type 2 diabetes who do not use insulin. Second, DexCom's recurring sensor revenue model creates a dependable and scalable financial profile, with gross margins historically above 60%. Third, expanding insurance and reimbursement coverage continues to widen access, including coverage for broader populations of people with Type 2 diabetes. Finally, the company's innovation pipeline — including longer-wear sensors and deeper integration with automated insulin delivery systems — supports its market position and long-term growth outlook. I’m watching this closely as the market evolves.
Key Risks for DXCM Investors
Investors should understand several risks before considering DXCM. Competition in the CGM market is intense, particularly from Abbott, and pricing pressure from insurers, pharmacy benefit managers, and managed care organizations can compress margins. The business is also subject to reimbursement risk, since coverage decisions by government and private payers directly influence demand and pricing. Manufacturing and supply-chain disruptions — including reliance on single-source suppliers for certain components — have at times affected product availability. Finally, DexCom operates in a highly regulated industry, and its products require regulatory clearance, while patent litigation and other legal matters can create uncertainty.
Integrating AI Tools Into Research
When analyzing companies in the healthcare space like DXCM, I often rely on Tickeron’s AI Screener to quickly compare fundamentals, trends, and patterns across the sector. It helps streamline the process of identifying how a stock measures up against peers without spending hours on manual screens. In my view, this kind of tool adds efficiency when evaluating long-term opportunities in medical devices.
Conclusion
DexCom has established itself as a leader in continuous glucose monitoring, transforming diabetes care from intermittent fingerstick testing to real-time, wearable sensing. Its combination of a recurring-revenue sensor model, a large and growing installed base, deep integration with insulin delivery technology, and expansion into over-the-counter biosensing distinguishes it within the medical device industry. While competition and reimbursement dynamics present ongoing challenges, DexCom's market position and innovation pipeline keep it a closely watched name for investors focused on healthcare technology.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DXCM saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for DXCM moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 62 similar instances where the indicator exited the overbought zone. In 48 of the 62 cases the stock moved lower. This puts the odds of a downward move at 77%.
Technical Analysis (Indicators)
Bearish Trend Analysis
DXCM moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DXCM crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXCM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for DXCM entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DXCM's RSI Indicator exited the oversold zone, 22 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on DXCM as a result. In 62 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for DXCM just turned positive on November 02, 2026. Looking at past instances where DXCM's MACD turned positive, the stock continued to rise in 31 of 45 cases over the following month. The odds of a continued upward trend are 69%.
Following a +6.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where DXCM advanced for three days, in 199 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
DXCM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 27 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. DXCM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.431) is normal, around the industry mean (4.142). P/E Ratio (30.779) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.332) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.988) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXCM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of medical devices and glucose monitoring systems
Industry MedicalNursingServices
Advertisement